Research programme: type 2 diabetes mellitus/obesity therapies - Zealand Pharma

Drug Profile

Research programme: type 2 diabetes mellitus/obesity therapies - Zealand Pharma

Alternative Names: ZP-1-98; ZP-3022; ZP-DI-70; ZP2435

Latest Information Update: 10 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Zealand Pharma
  • Class Antihyperglycaemics; Obesity therapies; Peptides
  • Mechanism of Action Gastric inhibitory polypeptide receptor agonists; Gastrin modulators; Glucagon-like peptide-1 receptor antagonists; Neuropeptide Y inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Obesity; Type 2 diabetes mellitus

Most Recent Events

  • 04 Oct 2017 Zealand Pharma and Torrey Pines Institute for Molecular Studies enter into a multi-target research collaboration to identify novel peptide therapeutics
  • 08 Jul 2015 Preclinical development is ongoing for Type-2 diabetes mellitus and Obesity in Denmark
  • 26 Sep 2013 Pharmacodynamics data from preclinical studies in Diabetes mellitus presented at the 49th Annual Meeting of the European Association for the Study of Diabetes (EASD-2013)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top